Ekf Diagnostics Holding PLC (LON:EKF)‘s stock had its “corporate” rating restated by N+1 Singer in a report released on Thursday.

Separately, Panmure Gordon reissued a “buy” rating and issued a GBX 21 ($0.27) price target on shares of Ekf Diagnostics Holding PLC in a report on Wednesday, March 15th.

Shares of Ekf Diagnostics Holding PLC (LON EKF) opened at 25.25 on Thursday. The company has a 50 day moving average of GBX 21.08 and a 200 day moving average of GBX 19.45. Ekf Diagnostics Holding PLC has a 52 week low of GBX 11.00 and a 52 week high of GBX 26.00. The firm’s market cap is GBX 117.23 million.

TRADEMARK VIOLATION WARNING: This news story was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/07/09/ekf-diagnostics-holding-plcs-ekf-corporate-rating-reiterated-at-n1-singer.html.

About Ekf Diagnostics Holding PLC

EKF Diagnostics Holdings plc is engaged in developing, manufacturing and supplying of products and services into the in-vitro diagnostic (IVD) market place. The Company manufactures and sells diagnostic instruments, reagents and certain ancillary products. The Company’s point-of-care range includes hemoglobin analyzers, HbA1c analyzers and glucose analyzers for use in the screening, monitoring and diagnosis of patients, as well as rapid tests for pregnancy and common infectious diseases.

Receive News & Ratings for Ekf Diagnostics Holding PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekf Diagnostics Holding PLC and related companies with MarketBeat.com's FREE daily email newsletter.